And as always please do feel free to #share & #retweet so that those on #Twitter / #FinTwit who are interested in #GeneEditing , #CRISPR , #BioTech & #Genomics will get this relevant data. Wishing you all a great #Week !

17/Beam Therapeutics’s strong financial status, its clinical advancement alongside massive #collaborations & #acquisitions strategy, IMO fortifies its status as a leading one-stop shop for all of the innovative #GeneEditing platforms: #BaseEditing , #PrimeEditing & #RNA platform (Orbital)

16/Beam Therapeutics’s upcoming Milestones:

Finish enrolment in the sentinel & expansion cohorts for $BEAM-101 in ‘23 + initial data in ‘24

Dose first $BEAM-201 patient by mid-‘23

IND filing for $BEAM-301 in late ‘23 / early ‘24

IND filing for $BEAM-302 in early ‘24

15/As of 12/31/22 $BEAM had capital resources of $1.07B & R&D expenses of $86.3M. IMO Beam Therapeutics’s current cash position of $1.1B will enable it to continue both to further develop its pipeline and to initiate additional acquisitions & collaborations at least into 2025.

14/Beam Therapeutics continues to expect operations at its #NorthCarolina manufacturing facility to commence in the first quarter of 2023 and expects to initiate current good manufacturing practice compliant operations in late 2023

13/Beam Therapeutics is IMO the #CRISPR company with the most extensive & vast collaboration agreements portfolio: 1)Verve Therapeutics - cardiovascular disease 2) $SANA - non-exclusive license for #Cas12 3)Prime Medicine-exclusive rights for #PrimeEditing for transition mutations. $APLS $PFE $PRME

12/@Beamtx is advancing its 2ND in vivo program - $BEAM-302 & in early 2024 plans to submit a regulatory application for authorization to initiate clinical trials. BEAM-302 is aimed to treat AATD - an inherited genetic disorder which cause early onset #emphysema & liver disease.

11/IND-enabling studies for $BEAM-301 continue, and by late 2023 or early 2024, Beam Therapeutics plans to submit a regulatory application for authorization to initiate clinical trials for the program.

10/ $BEAM-301 is a liver-targeting lipid nanoparticle (LNP) formulation of base editing reagents designed to correct the R83C mutation, the most common disease-causing mutation which results in the most severe form of #glycogen storage disease 1a (GSDIa)

9/In December ‘22, Beam Therapeutics had received clearance from the U.S. FDA for its #IND for $BEAM-201. Beam Therapeutics has already initiated a first-in-human Phase 1/2 clinical trial to evaluate the safety & efficacy of BEAM-201 and expects to dose the first patient by mid-‘23

🚨 DISRUPTOR’s Macro Update🧵
📊📊 Saturday March 25 📊📊

8 $BEAM-201 is the first quadruple-edited, #allogeneic CAR-T cell investigational therapy in clinical-stage development & is designed to target CD7 to treat relapsed/refractory T-cell acute lymphoblastic #leukemia T-ALL/T-cell lymphoblastic #lymphoma (T-LL)